MedTrace Logo

Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)

NCT00442338 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2022-02-02

Study results available
· View outcomes & findings →

Summary

The study estimates the efficacy and safety of MK0476 and aminophylline intravenous administration in adult participants with acute asthma.

Conditions

Interventions

DRUG

montelukast sodium

Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes

DRUG

montelukast sodium

Montelukast 14 mg single injection (IV bolus administration) over 5 minutes

DRUG

aminophylline hydrate

Aminophylline 250 mg IV drip infusion over 60 minutes

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-08-31
Completion
2007-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00442338 on ClinicalTrials.gov